Beechwood Hotel - Worcester, MA
363 Plantation Street
Worcester, MA 01605
www.beechwoodhotel.com
The National CML Society cordially invites you to join us for an evening with some of America's leading experts in the research and treatment of
Chronic Myelogenous Leukemia.
The experts will discuss:
CML: A Decade of Progress - A Future of PromiseMany new therapeutic advances are soon to be available for those living with CML. These advances include those that will further address mutations, as well as the eradication of Leukemic Stem Cells that could eventually lead to a cure for CML. This event is designed to introduce you to these emerging therapies and allow you the opportunity to interact with leading CML specialists and researchers.
Don’t miss this exciting opportunity!
About the presenters...(shown in order of appearance in program)
Alan G. Rosmarin, MD is the Gladys Smith Martin Professor of Oncology at the University of Massachusetts Medical School. He serves as Chief of the Division of Hematology/Oncology and Co-Director of the UMass Memorial Cancer Center of Excellence, which provides extensive research and clinical trials, expert diagnosis, treatment, and support of cancer patients. Dr. Rosmarin is an expert in the clinical management of hematologic malignancies, including leukemia, lymphoma, myeloma, and other blood disorders. His laboratory-based research has been supported by the National Institutes of Health and American Cancer Society. An author of more than seventy-five publications and abstracts, Dr. Rosmarin is routinely called on as a reviewer of manuscripts and grant applications, and is a member of the editorial boards of Stem Cells, Experimental Hematology, and the American Cancer Society. Dr. Rosmarin has served significant national roles in the American Cancer Society, the National Cancer Institute, and the American Society of Hematology.
Jayde Bednarik, PharmD, BCOP is a board certified clinical oncology pharmacist who works at UMass Memorial Medical Center. She is an adjunct professor at the UMass Memorial Graduate School of Nursing. Jayde primarily works with the bone marrow transplant group and patients who have been diagnosed with hematologic malignancies such as leukemia, lymphoma and multiple myeloma. She works in both the hospital and clinic setting to provide medication education to patients while aiding them with complex medication regimen management, high risk medications and supportive care for adverse effects from a patient's disease state or treatment. Jayde is currently working collaboratively to develop management strategies in patients taking oral chemotherapy agents with various health care providers in order to provide positive patient outcomes.
Jan Cerny, MD, PhD is an Assistant Professor of Medicine at the University of Massachusetts Medical School. He serves in the Leukemia and Bone Marrow Transplant Program at the Division of Hematology/Oncology. Dr. Cerny has also earned PhD in molecular biology of hematological malignancies and has an extensive background in basic and translational research in hematological malignancies. An expert in the clinical management of hematologic malignancies, especially leukemia, lymphoma, myeloma, as well as stem cell transplantation, he is co-investigator on several translational research projects in leukemia and myeloproliferative neoplasms. He is a Principal Investigator for two clinical trials in chronic myeloid leukemia, an author of more than forty publications and sixty five abstracts, and has been serving as a reviewer of manuscripts.
Shaoguang Li, MD, PhD is currently an Associate Professor of Medicine at the University of Massachusetts Medical School. Dr. Li leads an active and productive research laboratory focusing on understanding the biology of leukemia stem cells (LSCs) in BCR-ABL-induced chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The long-term goal of his research is to identify critical signaling molecules/pathways in CML and ALL for developing effective, selective and curative therapies through targeting these major pathways. He has identified several key genes that play critical roles in LSCs, among which the Alox5 gene was identified a couple of years ago and is being tested in an ongoing clinical trial. His research is funded by National Institutes of Health (NIH), Leukemia & Lymphoma Society (LLS) and other funding agencies. He is a frequent grant reviewer for the NIH and LLS, and a manuscript reviewer for top-tier journals including Nature Genetics, Journal of Clinical Investigation, Blood, etc.
This event is presented free of charge for all CML patients, their health care team, family and friends.
Dinner will be served.
Please note - reservations that include dinner must be received no later than 2:30pm EST - Monday, April 23. You may still register as "program only" reservations will remain open.
SPACE IS LIMITED - EARLY REGISTRATION SUGGESTED
The National CML Society gratefully acknowledges and thanks Novartis
for the unrestricted educational grant that helped make this event possible.